PCSK9 Inhibitors – Does the Benefit Outweigh the Cost?

The results of the GAUSS-3 trial were recently presented at the American College of Cardiology 65th Scientific Session & Expo and were published online in the Journal of the American Medical Association. How did the PCSK9 inhibitor perform among patients with statin intolerance? Was it found to be cost effective? Read more here. (Source: First Report Managed Care, 4/4/16)

You might also be interested in:

Scientist.com to Acquire HealthEconomics.Com, the World’s… 12/15/2020
[Webinar] How can VA/HTA Inform Policy Interventions and… 10/15/2020
EQRx Scales Disruptive Model of Important New Medicines 01/11/2021
Is Real-World Evidence Used in P&T Monographs and Therapeutic… 12/03/2020
ICER Announces New Governance Board Members in Push to Improve… 03/22/2021
Addressing the Affordability Crisis of Cell & Gene Therapies 12/16/2020
HTA Whitepaper Discusses Resulting Value and Economic Benefits 04/16/2021